Success Metrics

Active Trials

7(70%)

Phase Distribution

Ph phase_2

50%

Ph early_phase_1

10%

Ph phase_1

40%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution10 total trials

Early Phase 1First-in-human

1(10.0%)

Phase 1Safety & dosage

4(40.0%)

Phase 2Efficacy & side effects

5(50.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 0 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(10)

Detailed Status

Recruiting7

Not yet recruiting3

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

N/A

Most Advanced

Phase 2

Trials by Phase

Early Phase 11 (10.0%)

Phase 14 (40.0%)

Phase 25 (50.0%)

Trials by Status

recruiting770%

not_yet_recruiting330%

Recent Activity

7 active trials

Showing 5 of 10

recruitingphase_2

A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

NCT06855771

recruitingphase_1

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

NCT06672523

recruitingphase_2

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

NCT07283705

recruitingphase_2

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

NCT07063745

recruitingphase_1

A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors

NCT07077434

View all 10 trials

Clinical Trials (10)

Showing 10 of 10 trials

NCT06855771Phase 2

A Study of Navlimetostat (BMS-986504) in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion (MountainTAP-9)

Recruiting

NCT06672523Phase 1

A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Participants With Advanced Solid Tumors With Homozygous Methylthioadenosine Phosphorylase Deletion

Recruiting

NCT07283705Phase 2

A Phase II Study Evaluating BMS-986504 in MTAP-deleted Pancreatic Cancer

Recruiting

NCT07063745Phase 2

A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP Deletion

Recruiting

NCT07077434Phase 1

A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid Tumors

Recruiting

NCT07492680Phase 2

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Not Yet Recruiting

NCT07602946Phase 2

SELECTmeso A Trial for Patients With Relapsed Malignant Mesothelioma SELECTmeso1 A Trial of BMS-986504 in Patients With MTAP-deficient Relapsed Mesothelioma

Not Yet Recruiting

NCT07549022Phase 1

Safety and Efficacy of BMS-986504 in Unresectable Malignant Peripheral Nerve Sheath Tumor

Not Yet Recruiting

NCT07532902Phase 1

A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor Cancer

Recruiting

NCT06883747Early Phase 1

Clinical Trial of BMS-986504 in Recurrent GBM Patients

Recruiting

All 10 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 10